Skin squamous cell carcinoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:59 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Skin squamous cell carcinoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of INCB099280 for Patients With Advanced Cutaneous Squamous Cell Carcinoma Not Suitable for Surgery or Radiotherapy https://clinicaltrials.eu/trial/study-of-incb099280-for-patients-with-advanced-cutaneous-squamous-cell-carcinoma-not-suitable-for-surgery-or-radiotherapy/ Wed, 29 Apr 2026 14:26:57 +0000 https://clinicaltrials.eu/trial/study-of-incb099280-for-patients-with-advanced-cutaneous-squamous-cell-carcinoma-not-suitable-for-surgery-or-radiotherapy/ This clinical trial is focused on studying a type of skin cancer known as advanced cutaneous squamous cell carcinoma (cSCC). The trial is evaluating a new treatment called INCB099280, which is taken as a film-coated tablet. Participants in the study will include those who have not received prior immunotherapy and have either not been treated before or have a recurring form of this cancer that cannot be effectively treated with surgery or radiation.

The purpose of the study is to assess the safety and initial effectiveness of INCB099280 at different doses. Participants will take the medication orally, and the study will monitor their response to the treatment over a period of time. The trial will involve regular check-ups and assessments to ensure the safety and well-being of the participants while gathering data on how the cancer responds to the treatment.

Throughout the study, participants will be closely observed for any side effects or changes in their condition. The trial aims to provide valuable information on whether INCB099280 can be a safe and effective treatment option for those with advanced cSCC. The study is expected to continue until mid-2025, with participants receiving the treatment for a maximum of 24 weeks.

]]>